Targeting lung tumor environments to inhibit cancer growth
Official title: Toward Clinical Trial: AXL-STAT3 Targeting of Lung Tumor Microenvironments
Funded at University of Texas Hlth Science Center · NIH-11101315 · Data updated 2026-11-12
This study is looking at how certain signals in lung tumors help them grow and spread, and it hopes to find new ways to block those signals, which could lead to better treatments for lung cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $575,193 |
| NIH project number | 5R01CA269766-03 |
| Project ID | NIH-11101315 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung cancer who may benefit from novel therapeutic approaches targeting tumor microenvironments.
✕Less likely to help
Patients with non-cancerous conditions or those not diagnosed with lung cancer may not receive any benefit from this research.
What this research studies
This research investigates how specific signaling pathways, AXL and STAT3, contribute to the growth and spread of lung tumors. By examining the interactions between different cell types within the tumor microenvironment, the study aims to disrupt the communication that supports cancer progression. Patients may benefit from new therapeutic strategies that target these pathways, potentially leading to improved outcomes in lung cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer by disrupting the tumor-supporting environment.
How similar studies have gone: Other research has shown promising results in targeting similar signaling pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Taverna, Josephine a — University of Texas Hlth Science Center
- Study coordinator: Taverna, Josephine a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.